<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83208">
  <stage>Registered</stage>
  <submitdate>25/09/2008</submitdate>
  <approvaldate>12/03/2012</approvaldate>
  <actrnumber>ACTRN12612000284864</actrnumber>
  <trial_identification>
    <studytitle>A randomised controlled crossover pilot study of meropenem standard 30 minute infusion versus prolonged 3 hour infusion in intensive care patients</studytitle>
    <scientifictitle>A study of intensive care patients comparing meropenem 500mg 3 hour infusion versus 1g 30 minute infusion and time above mean inhibitory concentration</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>ClinicalTrials.gov: NCT00891423</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Sepsis</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Studies of infection and infectious agents</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Meropenem 500mg administered as a 3 hour infusion.  
Wash-out period between treatments of at least 24 hours.</interventions>
    <comparator>Meropenem 1g administered as a 30 minute infusion.
Wash-out period between treatments of at least 24 hours.</comparator>
    <control>Dose comparison</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Time above mean inhibitory concentration</outcome>
      <timepoint>During dosing interval (from start of infusion to prior to commencement of next infusion).  Eight hours if creatinine clearance equal or greater than 50 mls/min and 12 hours if less than 50 mls/min</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Nil</outcome>
      <timepoint>Nil</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Adult intensive care patients
Sepsis
Predicted duration of treatment more than 3 days</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>100</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Predicted duration of treatment &lt; 3 days
Hypersensitivity to meropenem or other beta-lactams</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Pharmacokinetics / pharmacodynamics</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>16/05/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>10</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>3084</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Austin Hospital</primarysponsorname>
    <primarysponsoraddress>Studley Road
Heidelberg
VIC  3084</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Austin Hospital</fundingname>
      <fundingaddress>Studley Road
Heidelberg
VIC  3084</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Meropenem is an antibiotic used in the treatment of serious infections.  This study aims to investigate whether giving meropenem a by a longer infusion (3 hours) but a lower dose, enables the antibiotic to be in the bloodstream for at least the same amount of time as a higher dose given over a short time (30 minutes).</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Austin Health Ethics Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate>15/12/2008</ethicapprovaldate>
      <hrec>H2008/03406</hrec>
      <ethicsubmitdate>15/10/2008</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Katherine Langan</name>
      <address>Austin Hospital
Studley Road
Heidelberg
VIC  3084</address>
      <phone>61394965000</phone>
      <fax />
      <email>klangan@netspace.net.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Katherine Langan</name>
      <address>Austin Hospital
Studley Road
Heidelberg
VIC  3084</address>
      <phone>61394965000</phone>
      <fax />
      <email>klangan@netspace.net.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Katherine Langan</name>
      <address>Austin Hospital
Studley Road
Heidelberg
VIC  3084</address>
      <phone>+61390766676</phone>
      <fax>+61390766677</fax>
      <email>klangan@netspace.net.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>